These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25454855)

  • 1. Use of placebos in Phase 1 preventive HIV vaccine clinical trials.
    Huang Y; Karuna ST; Janes H; Frahm N; Nason M; Edlefsen PT; Kublin JG; Corey L; McElrath MJ; Gilbert PB
    Vaccine; 2015 Feb; 33(6):749-52. PubMed ID: 25454855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Wolff M; Gorse GJ; Graham BS; Corey L; Clements-Mann ML; Verani-Ketter N; Erb S; Smith CM; Belshe RB; Wagner LJ; McElrath MJ; Schwartz DH; Fast P
    AIDS Res Hum Retroviruses; 1997 Sep; 13(14):1163-77. PubMed ID: 9310283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.
    Bellino S; Francavilla V; Longo O; Tripiciano A; Paniccia G; Arancio A; Fiorelli V; Scoglio A; Collacchi B; Campagna M; Lazzarin A; Tambussi G; Din CT; Visintini R; Narciso P; Antinori A; D'Offizi G; Giulianelli M; Carta M; Di Carlo A; Palamara G; Giuliani M; Laguardia ME; Monini P; Magnani M; Ensoli F; Ensoli B
    Rev Recent Clin Trials; 2009 Sep; 4(3):195-204. PubMed ID: 20028332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
    Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
    J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.
    Li D; Forrest BD; Li Z; Xue P; Hanson CV; Duan S; Cheng H; Li M; Wang CY; Koff WC
    Asian Pac J Allergy Immunol; 1997 Jun; 15(2):105-13. PubMed ID: 9346275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
    Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
    Trials; 2014 Feb; 15():68. PubMed ID: 24571662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization.
    Migasena S; Suntharasamai P; Pitisuttithum P; Kitayaporn D; Wasi C; Huang W; Vanichseni S; Koompong C; Kaewkungwal J; Raktham S; Ippolito T; Hanson C; Gregory T; Heyward WL; Berman P; Francis D
    AIDS Res Hum Retroviruses; 2000 May; 16(7):655-63. PubMed ID: 10791876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.
    Salmon-Céron D; Durier C; Desaint C; Cuzin L; Surenaud M; Hamouda NB; Lelièvre JD; Bonnet B; Pialoux G; Poizot-Martin I; Aboulker JP; Lévy Y; Launay O;
    AIDS; 2010 Sep; 24(14):2211-23. PubMed ID: 20625264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
    Ramanathan VD; Kumar M; Mahalingam J; Sathyamoorthy P; Narayanan PR; Solomon S; Panicali D; Chakrabarty S; Cox J; Sayeed E; Ackland J; Verlinde C; Vooijs D; Loughran K; Barin B; Lombardo A; Gilmour J; Stevens G; Smith MS; Tarragona-Fiol T; Hayes P; Kochhar S; Excler JL; Fast P
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1107-16. PubMed ID: 19943789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.
    Huang Y; DiazGranados C; Janes H; Huang Y; deCamp AC; Metch B; Grant S; Sanchez B; Phogat S; Koutsoukos M; Kanesa-Thasan N; Bourguignon P; Collard A; Buchbinder S; Tomaras GD; McElrath J; Gray G; Kublin JG; Corey L; Gilbert PB
    Curr Opin Virol; 2016 Apr; 17():57-65. PubMed ID: 26827165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect.
    Lhomme E; Hejblum BP; Lacabaratz C; Wiedemann A; Lelièvre JD; Levy Y; Thiébaut R; Richert L
    J Immunol Methods; 2020 Feb; 477():112711. PubMed ID: 31809708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
    Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
    PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
    Rerks-Ngarm S; Paris RM; Chunsutthiwat S; Premsri N; Namwat C; Bowonwatanuwong C; Li SS; Kaewkungkal J; Trichavaroj R; Churikanont N; de Souza MS; Andrews C; Francis D; Adams E; Flores J; Gurunathan S; Tartaglia J; O'Connell RJ; Eamsila C; Nitayaphan S; Ngauy V; Thongcharoen P; Kunasol P; Michael NL; Robb ML; Gilbert PB; Kim JH
    J Infect Dis; 2013 Apr; 207(8):1195-205. PubMed ID: 22837492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic vaccine trails in Thailand.
    Churdboonchart V
    J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand.
    Phanuphak P; Teeratakulpixarn S; Sarangbin S; Nookhai S; Ubolyam S; Sirivichayakul S; Leesavan A; Forrest BD; Hanson CV; Li M; Wang CY; Koff WC
    Asian Pac J Allergy Immunol; 1997 Mar; 15(1):41-8. PubMed ID: 9251847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.
    Schmidt C; Smith C; Barin B; Bakhtyari A; Bart PA; Bekker LG; Chomba E; Clumeck N; Ho D; Hoosen A; Jaoko W; Kaleebu P; Karita E; Keefer MC; van Lunzen J; McMichael A; Mehendale S; Peters B; Ramanathan VD; Robinson A; Rockstroh J; Vardas E; Vets E; Weber J; Graham BS; Than S; Excler JL; Kochhar S; Ho M; Heald A; Fast PE
    Hum Vaccin Immunother; 2012 May; 8(5):630-8. PubMed ID: 22634443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
    Mothe B; Climent N; Plana M; Rosàs M; Jiménez JL; Muñoz-Fernández MÁ; Puertas MC; Carrillo J; Gonzalez N; León A; Pich J; Arnaiz JA; Gatell JM; Clotet B; Blanco J; Alcamí J; Martinez-Picado J; Alvarez-Fernández C; Sánchez-Palomino S; Guardo AC; Peña J; Benito JM; Rallón N; Gómez CE; Perdiguero B; García-Arriaza J; Esteban M; López Bernaldo de Quirós JC; Brander C; García F;
    J Antimicrob Chemother; 2015; 70(6):1833-42. PubMed ID: 25724985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HIV-1 vaccination--is there hope?].
    Speck RF; Brander C; Kündig TM
    Ther Umsch; 2005 Oct; 62(10):695-702. PubMed ID: 16277037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.
    Spearman P; Kalams S; Elizaga M; Metch B; Chiu YL; Allen M; Weinhold KJ; Ferrari G; Parker SD; McElrath MJ; Frey SE; Fuchs JD; Keefer MC; Lubeck MD; Egan M; Braun R; Eldridge JH; Haynes BF; Corey L;
    Vaccine; 2009 Jan; 27(2):243-9. PubMed ID: 18996425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers.
    McFarland EJ; Johnson DC; Muresan P; Fenton T; Tomaras GD; McNamara J; Read JS; Douglas SD; Deville J; Gurwith M; Gurunathan S; Lambert JS
    AIDS; 2006 Jul; 20(11):1481-9. PubMed ID: 16847402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.